Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Entera Bio Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ENTX
Nasdaq
8731
https://enterabio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Entera Bio Ltd
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
- Mar 26th, 2024 12:30 pm
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
- Mar 25th, 2024 1:57 pm
12 Best Biotech Penny Stocks to Invest In
- Mar 24th, 2024 7:54 pm
We Think Entera Bio (NASDAQ:ENTX) Can Afford To Drive Business Growth
- Mar 23rd, 2024 1:11 pm
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
- Mar 20th, 2024 12:00 pm
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
- Mar 8th, 2024 9:05 pm
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Mar 4th, 2024 1:30 pm
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Jan 30th, 2024 1:30 pm
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
- Jan 3rd, 2024 1:00 pm
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
- Dec 26th, 2023 1:00 pm
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
- Nov 29th, 2023 1:30 pm
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
- Nov 14th, 2023 12:30 pm
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
- Nov 9th, 2023 7:30 pm
Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting
- Oct 16th, 2023 12:00 pm
OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations
- Sep 13th, 2023 5:18 pm
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
- Sep 12th, 2023 12:30 pm
Entera Bio to Participate in Upcoming Investor Conferences
- Sep 5th, 2023 12:00 pm
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth?
- Aug 24th, 2023 10:25 am
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting
- Aug 16th, 2023 12:30 pm
Entera Bio Announces Q2 2023 Financial Results and Corporate Updates
- Aug 11th, 2023 8:05 pm
Scroll